Online inquiry

IVTScrip™ mRNA-Anti-RABVgp4, CR4098(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ6209MR)

This product GTTS-WQ6209MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets RABVgp4 gene. The antibody can be applied in Rabies research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NP_056796.1
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 1489856
UniProt ID P08667
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-RABVgp4, CR4098(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) (GTTS-WQ6209MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ3900MR IVTScrip™ mRNA-Anti-CD274, BCD-135(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA BCD-135
GTTS-WQ15450MR IVTScrip™ mRNA-Anti-ERBB3, U3-1287(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA U3-1287
GTTS-WQ13380MR IVTScrip™ mRNA-Anti-PRLR, PR-1594804(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA PR-1594804
GTTS-WQ3094MR IVTScrip™ mRNA-Anti-FASLG, APG-101(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA APG-101
GTTS-WQ14272MR IVTScrip™ mRNA-Anti-CSF1R, RG7155(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA RG7155
GTTS-WQ6611MR IVTScrip™ mRNA-Anti-CD79B, DCDS0780A(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA DCDS0780A
GTTS-WQ2956MR IVTScrip™ mRNA-Anti-PDCD1, ANB-011(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA ANB-011
GTTS-WQ11031MR IVTScrip™ mRNA-Anti-ERBB2&ERBB3, MCLA-128(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA MCLA-128
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW